Edition:
United States

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Capital Market

10.05USD
1:01pm EDT
Change (% chg)

$0.20 (+2.03%)
Prev Close
$9.85
Open
$9.80
Day's High
$10.15
Day's Low
$9.60
Volume
48,088
Avg. Vol
147,037
52-wk High
$12.40
52-wk Low
$2.70

Latest Key Developments (Source: Significant Developments)

Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics
Wednesday, 10 Aug 2016 03:00pm EDT 

Mirati Therapeutics Inc : Broadfin Capital, LLC reports 5.02 pct passive stake in Mirati Therapeutics as of August 8, 2016 - SEC Filing Source - http://bit.ly/2aMdcIv Further company coverage: [MRTX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Mirati Therapeutics reports Q2 loss per share of $1.11
Thursday, 4 Aug 2016 04:01pm EDT 

Mirati Therapeutics Inc : Q2 loss per share $1.11 . Mirati therapeutics reports financial results and provides business update for the second quarter 2016 .Q2 earnings per share view $-1.15 -- Thomson Reuters I/B/E/S.  Full Article

Mirati Therapeutics, Inc announces leadership changes
Wednesday, 23 Mar 2016 08:30am EDT 

Mirati Therapeutics, Inc:Says promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016.  Full Article

Mirati Therapeutics Inc Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
Monday, 21 Dec 2015 08:09am EST 

Mirati Therapeutics Inc:Announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced.Also announced that "glesatinib" is the proposed generic name for MGCD265.  Full Article

BRIEF-Mirati Therapeutics presents positive data from on-going clinical trials of sitravatinib

* Mirati Therapeutics Inc presents positive preliminary data from on-going clinical trials of sitravatinib in non-small cell lung cancer